Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion

Authors: Synnove Norvoll Magnussen, Elin Hadler-Olsen, Daniela Elena Costea, Eli Berg, Cristiane Cavalcanti Jacobsen, Bente Mortensen, Tuula Salo, Inigo Martinez-Zubiaurre, Jan-Olof Winberg, Lars Uhlin-Hansen, Gunbjorg Svineng

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Urokinase plasminogen activator (uPA) receptor (uPAR) is up-regulated at the invasive tumour front of human oral squamous cell carcinoma (OSCC), indicating a role for uPAR in tumour progression. We previously observed elevated expression of uPAR at the tumour-stroma interface in a mouse model for OSCC, which was associated with increased proteolytic activity. The tumour microenvironment regulated uPAR expression, as well as its glycosylation and cleavage. Both full-length- and cleaved uPAR (uPAR (II-III)) are involved in highly regulated processes such as cell signalling, proliferation, migration, stem cell mobilization and invasion. The aim of the current study was to analyse tumour associated factors and their effect on uPAR cleavage, and the potential implications for cell proliferation, migration and invasion.

Methods

Mouse uPAR was stably overexpressed in the mouse OSCC cell line AT84. The ratio of full-length versus cleaved uPAR as analysed by Western blotting and its regulation was assessed by addition of different protease inhibitors and transforming growth factor - β1 (TGF-β1). The role of uPAR cleavage in cell proliferation and migration was analysed using real-time cell analysis and invasion was assessed using the myoma invasion model.

Results

We found that when uPAR was overexpressed a proportion of the receptor was cleaved, thus the cells presented both full-length uPAR and uPAR (II-III). Cleavage was mainly performed by serine proteases and urokinase plasminogen activator (uPA) in particular. When the OSCC cells were stimulated with TGF-β1, the production of the uPA inhibitor PAI-1 was increased, resulting in a reduction of uPAR cleavage. By inhibiting cleavage of uPAR, cell migration was reduced, and by inhibiting uPA activity, invasion was reduced. We could also show that medium containing soluble uPAR (suPAR), and cleaved soluble uPAR (suPAR (II-III)), induced migration in OSCC cells with low endogenous levels of uPAR.

Conclusions

These results show that soluble factors in the tumour microenvironment, such as TGF-β1, PAI-1 and uPA, can influence the ratio of full length and uPAR (II-III) and thereby potentially effect cell migration and invasion. Resolving how uPAR cleavage is controlled is therefore vital for understanding how OSCC progresses and potentially provides new targets for therapy.
Literature
1.
Funk GF, Karnell LH, Robinson RA, Zhen WK, Trask DK, Hoffman HT. Presentation, treatment, and outcome of oral cavity cancer: a National Cancer Data Base report. Head & neck. 2002;24:165–80.CrossRef
2.
Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993;328:184–94.CrossRefPubMed
3.
Boonstra MC, Verbeek FP, Mazar AP, Prevoo HA, Kuppen PJ, van de Velde CJ, Vahrmeijer AL, Sier CF. Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC Cancer. 2014;14:269.CrossRefPubMedPubMedCentral
4.
Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets. 2009;9:32–71.CrossRefPubMed
5.
de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev. 2004;24:13–39.CrossRefPubMed
6.
Lindberg P, Larsson A, Nielsen BS. Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. International journal of cancer Journal international du cancer. 2006;118:2948–56.CrossRefPubMed
7.
Bacchiocchi R, Rubini C, Pierpaoli E, Borghetti G, Procacci P, Nocini PF, Santarelli A, Rocchetti R, Ciavarella D, Lo Muzio L, Fazioli F. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study. BMC Cancer. 2008;8:220.CrossRefPubMedPubMedCentral
8.
McMahon BJ, Kwaan HC. Components of the Plasminogen-Plasmin system as biologic markers for cancer. Adv Exp Med Biol. 2015;867:145–56.CrossRefPubMed
9.
Svineng G, Magnussen S, Hadler-Olsen E. Plasmin and the plasminogen activator system in health and disease. In: Karamanos NK, editor. Extracellular matrix: Pathobiology and signaling. Germany: Walter de Gruyter GmbH & Co; 2012. p. 261–90.
10.
Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94:116–28.CrossRefPubMed
11.
Magnussen S, Rikardsen OG, Hadler-Olsen E, Uhlin-Hansen L, Steigen SE, Svineng G. Urokinase Plasminogen activator receptor (uPAR) and Plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral Squamous cell carcinomas (OSCC). PLoS One. 2014;9:e101895.CrossRefPubMedPubMedCentral
12.
Wagner VP, Cardoso PR, Dos Santos JN, Meurer L, Vargas PA, Fonseca FP, Carrard VC, Martins MD. Immunohistochemical study of TGF-beta1 in oral Leukoplakia and oral Squamous cell carcinoma: correlations between Clinicopathologic factors and overall survival. Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry. Appl Immunohistochem Mol Morphol. 2016;00:000–000.
13.
Logullo AF, Nonogaki S, Miguel RE, Kowalski LP, Nishimoto IN, Pasini FS, Federico MH, Brentani RR, Brentani MM. Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2003;32:139–45.CrossRef
14.
Lund LR, Romer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens RW, Dano K. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J. 1999;18:4645–56.CrossRefPubMedPubMedCentral
15.
Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932–43.CrossRefPubMed
16.
Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Cines DB, Mazar A, Lubkowski J. Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol. 2006;363:482–95.CrossRefPubMedPubMedCentral
17.
Lin L, Gardsvoll H, Huai Q, Huang M, Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem. 2010;285:10982–92.CrossRefPubMedPubMedCentral
18.
Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, Stura EA, Menez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005;24:1655–63.CrossRefPubMedPubMedCentral
19.
Hoyer-Hansen G, Ronne E, Solberg H, Behrendt N, Ploug M, Lund LR, Ellis V, Dano K. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem. 1992;267:18224–9.PubMed
20.
Hoyer-Hansen G, Pessara U, Holm A, Pass J, Weidle U, Dano K, Behrendt N. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. The Biochemical journal. 2001;358:673–9.CrossRefPubMedPubMedCentral
21.
Andolfo A, English WR, Resnati M, Murphy G, Blasi F, Sidenius N. Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost. 2002;88:298–306.PubMed
22.
Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost. 2005;93:192–8.PubMed
23.
Hoyer-Hansen G, Ploug M, Behrendt N, Ronne E, Dano K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. European journal of biochemistry / FEBS. 1997;243:21–6.CrossRef
24.
Behrendt N, Ronne E, Dano K. Domain interplay in the urokinase receptor. Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J Biol Chem. 1996;271:22885–94.CrossRefPubMed
25.
Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Dano K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem. 1991;266:7842–7.PubMed
26.
Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010;584:1923–30.CrossRefPubMed
27.
Mazzieri R, D'Alessio S, Kenmoe RK, Ossowski L, Blasi F. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol Biol Cell. 2006;17:367–78.CrossRefPubMedPubMedCentral
28.
Montuori N, Ragno P. Multiple activities of a multifaceted receptor: roles of cleaved and soluble uPAR. Front Biosci (Landmark Ed). 2009;14:2494–503.CrossRef
29.
Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brunner N, Dano K, Hoyer-Hansen G, Lilja H. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem. 2006;52:838–44.CrossRefPubMed
30.
Almasi CE, Brasso K, Iversen P, Pappot H, Hoyer-Hansen G, Dano K, Christensen IJ. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer. Prostate. 2011;71:899–907.CrossRefPubMed
31.
Almasi CE, Drivsholm L, Pappot H, Hoyer-Hansen G, Christensen IJ. The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2013;121:189–96.CrossRefPubMed
32.
Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Hoyer-Hansen G, Smith K, Brunner N, Harris AL. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002;8:1132–41.
33.
Tjwa M, Sidenius N, Moura R, Jansen S, Theunissen K, Andolfo A, De Mol M, Dewerchin M, Moons L, Blasi F, et al. Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells. J Clin Invest. 2009;119:1008–18.PubMedPubMedCentral
34.
Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood. 2005;105:2198–205.CrossRefPubMed
35.
Magnussen S, Hadler-Olsen E, Latysheva N, Pirila E, Steigen SE, Hanes R, Salo T, Winberg JO, Uhlin-Hansen L, Svineng G. Tumour microenvironments induce expression of Urokinase Plasminogen activator receptor (uPAR) and concomitant activation of Gelatinolytic enzymes. PLoS One. 2014;9:e105929.CrossRefPubMedPubMedCentral
36.
Salo T, Vered M, Bello IO, Nyberg P, Bitu CC, Zlotogorski Hurvitz A, Dayan D. Insights into the role of components of the tumor microenvironment in oral carcinoma call for new therapeutic approaches. Exp Cell Res. 2014;325:58–64.CrossRefPubMed
37.
Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Frontiers in bioscience : a journal and virtual library. 2008;13:453–61.CrossRef
38.
Costea DE, Hills A, Osman AH, Thurlow J, Kalna G, Huang X, Pena Murillo C, Parajuli H, Suliman S, Kulasekara KK, et al. Identification of two distinct carcinoma-associated fibroblast subtypes with differential tumor-promoting abilities in oral squamous cell carcinoma. Cancer Res. 2013;73:3888–901.CrossRefPubMed
39.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–55.CrossRefPubMed
40.
Schultz-Hector S, Haghayegh S. Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res. 1993;53:1444–9.PubMed
41.
Lou E, Kellman RM, Hutchison R, Shillitoe EJ. Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. Oral Dis. 2003;9:305–12.CrossRefPubMed
42.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.CrossRefPubMed
43.
Hadler-Olsen E, Kanapathippillai P, Berg E, Svineng G, Winberg JO, Uhlin-Hansen L. Gelatin in situ zymography on fixed, paraffin-embedded tissue: zinc and ethanol fixation preserve enzyme activity. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 2010;58:29–39.CrossRef
44.
Cauwe B, Van den Steen PE, Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol. 2007;42:113–85.CrossRefPubMed
45.
Madsen CD, Ferraris GM, Andolfo A, Cunningham O, Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J Cell Biol. 2007;177:927–39.CrossRefPubMedPubMedCentral
46.
Hillig T, Engelholm LH, Ingvarsen S, Madsen DH, Gardsvoll H, Larsen JK, Ploug M, Dano K, Kjoller L, Behrendt N. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. J Biol Chem. 2008;283:15217–23.CrossRefPubMedPubMedCentral
47.
Jo M, Lester RD, Montel V, Eastman B, Takimoto S, Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem. 2009;284:22825–33.CrossRefPubMedPubMedCentral
48.
Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol. 2007;178:425–36.CrossRefPubMedPubMedCentral
49.
Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J Immunol. 2004;172:540–9.CrossRefPubMed
50.
Sundquist E, Renko O, Salo S, Magga J, Cervigne NK, Nyberg P, Risteli J, Sormunen R, Vuolteenaho O, Zandonadi F, et al. Neoplastic extracellular matrix environment promotes cancer invasion in vitro. Exp Cell Res. 2016;344:229–40.CrossRefPubMed
51.
Lund LR, Ellis V, Ronne E, Pyke C, Dano K. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. The Biochemical journal. 1995;310(Pt 1):345–52.CrossRefPubMedPubMedCentral
52.
Sieuwerts AM, Klijn JG, Henzen-Logmand SC, Bouwman I, Van Roozendaal KE, Peters HA, Setyono-Han B, Foekens JA. Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells. International journal of cancer Journal international du cancer. 1998;76:829–35.CrossRefPubMed
53.
Bernstein AM, Twining SS, Warejcka DJ, Tall E, Masur SK. Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation. Mol Biol Cell. 2007;18:2716–27.CrossRefPubMedPubMedCentral
54.
Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci. 1994;15:25–9.CrossRefPubMed
55.
Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol. 1990;111:757–63.CrossRefPubMed
56.
Wilkins-Port CE, Higgins PJ. Regulation of extracellular matrix remodeling following transforming growth factor-beta1/epidermal growth factor-stimulated epithelial-mesenchymal transition in human premalignant keratinocytes. Cells Tissues Organs. 2007;185:116–22.CrossRefPubMed
57.
Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol. 1990;68:1–19.CrossRefPubMed
58.
Czekay RP, Kuemmel TA, Orlando RA, Farquhar MG. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell. 2001;12:1467–79.CrossRefPubMedPubMedCentral
59.
Webb DJ, Nguyen DH, Sankovic M, Gonias SL. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. J Biol Chem. 1999;274:7412–20.CrossRefPubMed
60.
Nurmenniemi S, Sinikumpu T, Alahuhta I, Salo S, Sutinen M, Santala M, Risteli J, Nyberg P, Salo T. A novel organotypic model mimics the tumor microenvironment. Am J Pathol. 2009;175:1281–91.CrossRefPubMedPubMedCentral
61.
Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997;16:7279–86.CrossRefPubMedPubMedCentral
62.
Wilhelm OG, Wilhelm S, Escott GM, Lutz V, Magdolen V, Schmitt M, Rifkin DB, Wilson EL, Graeff H, Brunner G. Cellular glycosylphosphatidylinositol-specific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol. 1999;180:225–35.CrossRefPubMed
63.
Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K: Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991, 266:1926-1933.
64.
Resnati M, Pallavicini I, Wang JM, Oppenheim J, Serhan CN, Romano M, Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci U S A. 2002;99:1359–64.CrossRefPubMedPubMedCentral
65.
Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem. 2002;277:46932–9.CrossRefPubMed
66.
de Paulis A, Montuori N, Prevete N, Fiorentino I, Rossi FW, Visconte V, Rossi G, Marone G, Ragno P. Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. J Immunol. 2004;173:5739–48.CrossRefPubMed
67.
Montuori N, Cosimato V, Rinaldi L, Rea VE, Alfano D, Ragno P. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors. Thromb Haemost. 2013;109:309–18.CrossRefPubMed
68.
Degryse B, Resnati M, Rabbani SA, Villa A, Fazioli F, Blasi F. Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. Blood. 1999;94:649–62.PubMed
69.
Trigwell S, Wood L, Jones P. Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck). Biochem Biophys Res Commun. 2000;278:440–6.CrossRefPubMed
70.
Gilder AS, Jones KA, Hu J, Wang L, Chen CC, Carter BS, Gonias SL. Soluble Urokinase receptor is released selectively by Glioblastoma cells that express epidermal growth factor receptor variant III and promotes tumor cell migration and invasion. J Biol Chem. 2015;290:14798–809.CrossRefPubMedPubMedCentral
71.
Wahlberg K, Hoyer-Hansen G, Casslen B. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res. 1998;58:3294–8.PubMed
72.
Almasi CE, Christensen IJ, Hoyer-Hansen G, Dano K, Pappot H, Dienemann H, Muley T. Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis. Lung Cancer. 2011;74:510–5.CrossRefPubMed
73.
Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29:117–29.CrossRefPubMed
74.
75.
Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65–74.CrossRefPubMed
76.
Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002;3:349–63.CrossRefPubMed
77.
Lewis MP, Lygoe KA, Nystrom ML, Anderson WP, Speight PM, Marshall JF, Thomas GJ. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer. 2004;90:822–32.CrossRefPubMedPubMedCentral
78.
Harper J, Sainson RC. Regulation of the anti-tumour immune response by cancer-associated fibroblasts. Semin Cancer Biol. 2014;25:69–77.CrossRefPubMed
79.
80.
de-Assis EM, Pimenta LG, Costa-e-Silva E, Souza PE, Horta MC: Stromal myofibroblasts in oral leukoplakia and oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2012, 17:e733-e738.
Metadata
Title
Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion
Authors
Synnove Norvoll Magnussen
Elin Hadler-Olsen
Daniela Elena Costea
Eli Berg
Cristiane Cavalcanti Jacobsen
Bente Mortensen
Tuula Salo
Inigo Martinez-Zubiaurre
Jan-Olof Winberg
Lars Uhlin-Hansen
Gunbjorg Svineng
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3349-7

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer

Research article

Breast cancer patient delay in Fukushima, Japan following the 2011 triple disaster: a long-term retrospective study

Research article

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer

Study protocol

Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

Research article

miR-663a regulates growth of colon cancer cells, after administration of antimicrobial peptides, by targeting CXCR4-p21 pathway

Study protocol

Implementing exercise in cancer care: study protocol to evaluate a community-based exercise program for people with cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits